MYH11 and leukemia: Based on the lead compound, they found that AI-10-49 selectively binds to CBFβ-SMMHC and disrupts its binding to RUNX1, which thus restores RUNX1 transcriptional activity, displays favorable pharmacokinetics and delays leukemia progression in mice.